Continue to Site

Drug Discovery and Development

Essent Biologics debuts stem cell offerings for biopharma and cell therapy research

By |

Essent BiologicsAlloSource (Centennial, Colo.), a central U.S. provider of allograft providers, has founded a separate nonprofit known as Essent Biologics to provide human-derived biomaterials for research. Essent has recently launched a human mesenchymal stem cells (hMSCs) offering for a range of research applications. 

“The mission for the nonprofit is to maximize that gift of donation,” said Derek Mathers, head of business development at Essent Biologics. 

Each vial of hMSCs contains more than one million cells after thawing. They have a passage level of P0 or P1 to ensure potency.

The company offers stem cells produced under current Good Manufacturing Practices (cGMP) and in accordance with International Society for Cell & Gene Therapy (ISCT) guidelines. 

The company’s scientists have discovered a method for isolating cells and scaffold materials from tissue donation. The resulting cells are the first human-derived cell product that doesn’t use animal products or antibiotics in their processing, Mathers said. 

From a single donation, Essent Biologics can produce approximately 1.5 billion primary cells, and approximately 1 kg of scaffold materials for regenerative medicine purposes.

Essent can provide information about the origin of stem cells. “Traditionally, it’s been very difficult to tell exactly what donor human mesenchymal stem cells came from,” Mathers explained. “Our whole vision is to pair real human tissue from the donor with comprehensive donor information but still protect that donor’s identity,” he said. 

Essent can specify, for instance, if a donor was a smoker, their BMI and lifestyle factors, and whether they had any specific diseases. “We typically provide healthy cells,” but human disease tissue can potentially enable researchers to reduce or eliminate the need for testing with animal products. “Human cells are the most relevant biology for human therapies that they’re developing,” Mathers concluded. 

Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: , , , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development